HRP20130250T1 - Modificirani bakteriofag, koji sadrži gen za mali alfa/beta protein spora topljiv u kiselinama (sasp) - Google Patents
Modificirani bakteriofag, koji sadrži gen za mali alfa/beta protein spora topljiv u kiselinama (sasp) Download PDFInfo
- Publication number
- HRP20130250T1 HRP20130250T1 HRP20130250AT HRP20130250T HRP20130250T1 HR P20130250 T1 HRP20130250 T1 HR P20130250T1 HR P20130250A T HRP20130250A T HR P20130250AT HR P20130250 T HRP20130250 T HR P20130250T HR P20130250 T1 HRP20130250 T1 HR P20130250T1
- Authority
- HR
- Croatia
- Prior art keywords
- bacteriophage
- modified bacteriophage
- sasp
- modified
- gene
- Prior art date
Links
- 241001515965 unidentified phage Species 0.000 title claims 26
- 108090000623 proteins and genes Proteins 0.000 title claims 10
- 102000004169 proteins and genes Human genes 0.000 title claims 3
- 101100109158 Mus musculus Asprv1 gene Proteins 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 claims 6
- 241000894006 Bacteria Species 0.000 claims 3
- 101150031187 fba gene Proteins 0.000 claims 2
- 101150108901 fbaA gene Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 241000194107 Bacillus megaterium Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 101100447530 Dictyostelium discoideum gpi gene Proteins 0.000 claims 1
- 241000724233 Staphylococcus virus 11 Species 0.000 claims 1
- 101100120969 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) pgi1 gene Proteins 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 101150037483 bkdA gene Proteins 0.000 claims 1
- 229910052793 cadmium Inorganic materials 0.000 claims 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 230000001937 non-anti-biotic effect Effects 0.000 claims 1
- 101150084945 pdhA gene Proteins 0.000 claims 1
- 101150053253 pgi gene Proteins 0.000 claims 1
- 150000003248 quinolines Chemical group 0.000 claims 1
- 101150078369 rpsB gene Proteins 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00041—Use of virus, viral particle or viral elements as a vector
- C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
Claims (15)
1. Modificirani bakteriofag koji može inficirati ciljnu bakteriju, naznačen time što bakteriofag sadrži gen za mali α/β protein spora topljiv u kiselinama (SASP), koji kodira SASP, toksin za ciljnu bakteriju, gdje je gen SASP pod kontrolom konstitutivnog promotora koji je stran bakteriofagu i genu SASP, navedeni promotor je dovoljno jak da pogoni proizvodnju toksičnih razina SASP kada je modificirani bakteriofag prisutan u više kopija u ciljnoj bakteriji, a bakteriofag može formirati lizogen koji sadrži jednu kopiju gena SASP u proizvodnom soju bakterijskog domaćina.
2. Modificirani bakteriofag u skladu s patentnim zahtjevom 2, naznačen time što SASP sadrži SASPC iz B. megaterium.
3. Modificirani bakteriofag u skladu s patentnim zahtjevom 1 ili patentni zahtjev 2, naznačen time što sadrži modificirani bakteriofag koji napada S. aureus.
4. Modificirani bakteriofag u skladu s patentnim zahtjevom 3, naznačen time što je bakteriofag koji napada S. aureus bakteriofag φ11.
5. Modificirani bakteriofag u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se promotor bira između pdhA, rpsB, pgi, fbaA i sljedova koji su im identični preko 90%.
6. Modificirani bakteriofag u skladu s patentnim zahtjevom 5, naznačen time što je bakterijski promotor fbaA iz S. aureus.
7. Modificirani bakteriofag u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je nelitički, gdje se izborno gen SASP ubacuje u bakteriofagov gen za lizu.
8. Modificirani bakteriofag u skladu s patentnim zahtjevom 7, naznačen time što je holin.
9. Modificirani bakteriofag u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno sadrži neantibiotski marker za otpornost, primjerice marker za otpornost na kadmij.
10. Pripravak za zaustavljanje ili sprječavanje rast bakterijskih stanica, naznačen time što sadrži modificirani bakteriofag u skladu s bilo kojim od prethodnih patentnih zahtjeva i odgovarajuću podlogu.
11. Pripravak u skladu s patentnim zahtjevom 10, naznačen time što je formuliran za topikalnu upotrebu.
12. Modificirani bakteriofag u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi kao medikament.
13. Upotreba modificiranog bakteriofaga u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što je modificirani bakteriofag namijenjen upotrebi kao neterapijski bakterijski dekontaminans.
14. Modificirani bakteriofag u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi u zaustavljanju ili sprječavanju bakterijske infekcije.
15. Postupak proizvodnje modificiranog bakteriofaga koji može inficirati ciljnu bakteriju, naznačen time što se navedeni postupak sastoji u uzgoju bakterijskog domaćina koji sadrži genski materijal koji kodira bakteriofag u skladu s bilo kojim od prethodnih patentnih zahtjeva u mediju za uzgoj; poticanju bakteriofaga da se replicira u bakterijskom domaćinu; te prikupljanju bakteriofaga.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0715416.4A GB0715416D0 (en) | 2007-08-07 | 2007-08-07 | Modified bacteriophage |
| PCT/EP2008/060360 WO2009019293A1 (en) | 2007-08-07 | 2008-08-06 | Modified bacteriophage including an alpha/beta small acid-soluble spore protein (sasp) gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130250T1 true HRP20130250T1 (hr) | 2013-04-30 |
Family
ID=38543208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130250AT HRP20130250T1 (hr) | 2007-08-07 | 2013-03-21 | Modificirani bakteriofag, koji sadrži gen za mali alfa/beta protein spora topljiv u kiselinama (sasp) |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US8697049B2 (hr) |
| EP (1) | EP2179035B8 (hr) |
| JP (3) | JP5582354B2 (hr) |
| AU (1) | AU2008285659B2 (hr) |
| CA (1) | CA2695939C (hr) |
| DK (1) | DK2179035T3 (hr) |
| ES (1) | ES2402176T3 (hr) |
| GB (2) | GB0715416D0 (hr) |
| HR (1) | HRP20130250T1 (hr) |
| PL (1) | PL2179035T3 (hr) |
| PT (1) | PT2179035E (hr) |
| SI (1) | SI2179035T1 (hr) |
| WO (1) | WO2009019293A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0715416D0 (en) | 2007-08-07 | 2007-09-19 | Phico Therapeutics Ltd | Modified bacteriophage |
| GB201417810D0 (en) * | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modifying bacteriophage |
| GB201417808D0 (en) * | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modified bacteriophage |
| GB201417805D0 (en) * | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modifield bacteriophage |
| GB201417811D0 (en) * | 2014-10-08 | 2014-11-19 | Phico Therapeutics Ltd | Modifying bacteriophage |
| JP6842417B2 (ja) | 2014-12-16 | 2021-03-17 | シー３ジェイ セラピューティクス インコーポレイテッド | インビトロウイルスゲノム工学のための組成物及びその方法 |
| GB2544956A (en) * | 2015-07-08 | 2017-06-07 | Phico Therapeutics Ltd | Polypeptides, polynucleotides and uses thereof |
| GB201600075D0 (en) * | 2016-01-03 | 2016-02-17 | Glaxosmithkline Biolog Sa | Immunogenci composition |
| US10736928B2 (en) | 2016-01-20 | 2020-08-11 | Richard Brian Murphy, JR. | Pegylated recombinant bacteriophage |
| LT3440200T (lt) * | 2016-04-08 | 2021-05-25 | Phico Therapeutics Ltd | Modifikuotas bakteriofagas |
| WO2017174809A1 (en) * | 2016-04-08 | 2017-10-12 | Phico Therapeutics Ltd | Modifying bacteriophage |
| WO2019140534A1 (en) * | 2018-01-19 | 2019-07-25 | Cytophage Technologies Inc. | Genetically engineered bacteriophage |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0028130D0 (en) * | 2000-11-17 | 2001-01-03 | Phico Therapeutics Ltd | Polypeptide and uses thereof |
| GB0314469D0 (en) * | 2003-06-20 | 2003-07-23 | Phico Therapeutics Ltd | Antimicrobial compositions and uses thereof |
| DE102004061846A1 (de) * | 2004-12-22 | 2006-07-13 | Basf Ag | Mehrfachpromotoren |
| US8691542B2 (en) * | 2005-09-09 | 2014-04-08 | Cytex Therapeutics, Inc. | Tissue engineering methods and compositions |
| GB0715416D0 (en) | 2007-08-07 | 2007-09-19 | Phico Therapeutics Ltd | Modified bacteriophage |
-
2007
- 2007-08-07 GB GBGB0715416.4A patent/GB0715416D0/en not_active Ceased
-
2008
- 2008-08-06 ES ES08786965T patent/ES2402176T3/es active Active
- 2008-08-06 EP EP08786965A patent/EP2179035B8/en active Active
- 2008-08-06 SI SI200830934T patent/SI2179035T1/sl unknown
- 2008-08-06 PT PT87869657T patent/PT2179035E/pt unknown
- 2008-08-06 PL PL08786965T patent/PL2179035T3/pl unknown
- 2008-08-06 US US12/672,311 patent/US8697049B2/en active Active
- 2008-08-06 WO PCT/EP2008/060360 patent/WO2009019293A1/en active Application Filing
- 2008-08-06 AU AU2008285659A patent/AU2008285659B2/en active Active
- 2008-08-06 CA CA2695939A patent/CA2695939C/en active Active
- 2008-08-06 JP JP2010519462A patent/JP5582354B2/ja active Active
- 2008-08-06 GB GB0814385A patent/GB2451750B/en active Active
- 2008-08-06 DK DK08786965.7T patent/DK2179035T3/da active
-
2013
- 2013-03-21 HR HRP20130250AT patent/HRP20130250T1/hr unknown
-
2014
- 2014-02-26 US US14/190,727 patent/US9359596B2/en active Active - Reinstated
- 2014-04-25 JP JP2014091051A patent/JP2014221038A/ja active Pending
-
2016
- 2016-01-14 JP JP2016005268A patent/JP6177357B2/ja active Active
- 2016-05-05 US US15/147,483 patent/US10106784B2/en active Active
-
2018
- 2018-09-12 US US16/128,558 patent/US11559560B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2179035T3 (da) | 2013-04-08 |
| EP2179035B1 (en) | 2013-02-27 |
| PL2179035T3 (pl) | 2013-08-30 |
| JP6177357B2 (ja) | 2017-08-09 |
| GB0814385D0 (en) | 2008-09-10 |
| JP2016144444A (ja) | 2016-08-12 |
| US20160319244A1 (en) | 2016-11-03 |
| SI2179035T1 (sl) | 2013-05-31 |
| US20140242032A1 (en) | 2014-08-28 |
| US10106784B2 (en) | 2018-10-23 |
| JP2014221038A (ja) | 2014-11-27 |
| EP2179035A1 (en) | 2010-04-28 |
| US20190071648A1 (en) | 2019-03-07 |
| US20100239536A1 (en) | 2010-09-23 |
| EP2179035B8 (en) | 2013-04-03 |
| JP2010535482A (ja) | 2010-11-25 |
| PT2179035E (pt) | 2013-04-04 |
| JP5582354B2 (ja) | 2014-09-03 |
| US11559560B2 (en) | 2023-01-24 |
| GB2451750B (en) | 2010-06-02 |
| US8697049B2 (en) | 2014-04-15 |
| AU2008285659A1 (en) | 2009-02-12 |
| CA2695939A1 (en) | 2009-02-12 |
| ES2402176T3 (es) | 2013-04-29 |
| CA2695939C (en) | 2013-11-19 |
| GB0715416D0 (en) | 2007-09-19 |
| WO2009019293A1 (en) | 2009-02-12 |
| US9359596B2 (en) | 2016-06-07 |
| AU2008285659B2 (en) | 2013-09-19 |
| GB2451750A (en) | 2009-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130250T1 (hr) | Modificirani bakteriofag, koji sadrži gen za mali alfa/beta protein spora topljiv u kiselinama (sasp) | |
| Records | The type VI secretion system: a multipurpose delivery system with a phage-like machinery | |
| Andrés-Barrao et al. | Complete genome sequence analysis of Enterobacter sp. SA187, a plant multi-stress tolerance promoting endophytic bacterium | |
| Patiño-Navarrete et al. | Evolutionary processes and environmental factors underlying the genetic diversity and lifestyles of Bacillus cereus group bacteria | |
| Heuer et al. | Effects of T4 lysozyme release from transgenic potato roots on bacterial rhizosphere communities are negligible relative to natural factors | |
| Djukic et al. | How to kill the honey bee larva: genomic potential and virulence mechanisms of Paenibacillus larvae | |
| Xu et al. | Enhanced control of cucumber wilt disease by Bacillus amyloliquefaciens SQR9 by altering the regulation of its DegU phosphorylation | |
| Riera et al. | Characterization of antimicrobial-producing beneficial bacteria isolated from Huanglongbing escape citrus trees | |
| Gebhart et al. | Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile | |
| Ruffner et al. | Evolutionary patchwork of an insecticidal toxin shared between plant-associated pseudomonads and the insect pathogens Photorhabdus and Xenorhabdus | |
| Mitchell et al. | Treponema denticola biofilm-induced expression of a bacteriophage, toxin–antitoxin systems and transposases | |
| Berglund et al. | Run-off replication of host-adaptability genes is associated with gene transfer agents in the genome of mouse-infecting Bartonella grahamii | |
| Wei et al. | hpaR, a putative marR family transcriptional regulator, is positively controlled by HrpG and HrpX and involved in the pathogenesis, hypersensitive response, and extracellular protease production of Xanthomonas campestris pathovar campestris | |
| She et al. | Identification and genetic characterization of Ralstonia solanacearum species complex isolates from Cucurbita maxima in China | |
| Mohr et al. | Naturally occurring nonpathogenic isolates of the plant pathogen Pseudomonas syringae lack a type III secretion system and effector gene orthologues | |
| Fortier | Bacteriophages contribute to shaping Clostridioides (Clostridium) difficile species | |
| de Souza Duarte et al. | Hyicin 4244, the first sactibiotic described in staphylococci, exhibits an anti-staphylococcal biofilm activity | |
| Zhang et al. | Three new Pierce's disease pathogenicity effectors identified using Xylella fastidiosa biocontrol strain EB92-1 | |
| Andrade et al. | The Tad pilus apparatus of ‘Candidatus Liberibacter asiaticus’ and its regulation by VisNR | |
| de Oliveira et al. | clpB, a class III heat-shock gene regulated by CtsR, is involved in thermotolerance and virulence of Enterococcus faecalis | |
| Ahmed et al. | Plant-microbe interaction: mining the impact of native Bacillus amyloliquefaciens WS-10 on tobacco bacterial wilt disease and rhizosphere microbial communities | |
| Hasegawa et al. | Anchoring and length regulation of Porphyromonas gingivalis Mfa1 fimbriae by the downstream gene product Mfa2 | |
| Teper et al. | Consequences of adaptation of TAL effectors on host susceptibility to Xanthomonas | |
| Schultze et al. | A detailed view of the intracellular transcriptome of Listeria monocytogenes in murine macrophages using RNA-seq | |
| Sahu et al. | An MFS Transporter‐Like ORF from MDR Acinetobacter baumannii AIIMS 7 Is Associated with Adherence and Biofilm Formation on Biotic/Abiotic Surface |